2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1836

Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1820

Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient

4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: Abstract Number: 1792

Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1811

Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1801

Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs

4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: Abstract Number: 1825

Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: Abstract Number: 1818

Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study

4M096: Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Miscellaneous (1818–1823)

2:30PM-4:00PM: Abstract Number: 1781

Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1789

Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1812

Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: Abstract Number: 1826

Describing Intra-Individual Cognitive Function Course over Time in Lupus Patients: Persistent and Fluctuating Cognitive Impairment, Affected Cognitive Domains, and Severity

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: Abstract Number: 1793

Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1839

Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1846

Does Cartilage Loss Cause Pain in Osteoarthritis?

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1795

Education of Rheumatology Faculty: Evaluation of an Interactive Team Based Approach versus Traditional Didactic Teaching

4M089: Education (1794–1799)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].